ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
General Health & Fitness
Health & Wellness
Beta Blockers Extend Life in Melanoma Patients: Penn State Study
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="CoastWatcher" data-source="post: 92725" data-attributes="member: 2624"><p>Researchers at Penn State found that melanoma patients who received immunotherapy while taking a specific type of beta blocker lived longer than patients who received immunotherapy alone. In a follow-up experiment with mice, the researchers saw the same results. Dr. Todd Schell, professor of microbiology and immunology at Penn State College of Medicine, said that because beta blockers are already widely available, the findings -- published in the journal <em>OncoImmunology</em> -- could indicate a simple way for physicians to better treat their patients.</p><p></p><ul> <li data-xf-list-type="ul">"The type of beta blocker we found to be effective against melanoma -- pan beta blockers -- was actually the least prescribed," Schell said. "Most patients are either prescribed beta 1 selective blockers or are not taking beta blockers at all. This means there's a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy. And because beta blockers are already FDA approved, it's something we know is safe and can be very quickly implemented in patient care."</li> <li data-xf-list-type="ul">While there was little difference in how long patients taking beta 1-selective blockers or no beta blockers lived, the results indicate that patients taking pan beta blockers lived significantly longer than the others. Five years after immunotherapy, about 70 percent of patients receiving pan beta blockers were still alive, versus about 25 percent of those taking beta 1-selective blockers or no beta blockers at all.</li> </ul><p></p><p>"Beta Blockers May Boost Immunotherapy, Help Melanoma Patients Live Longer," <a href="https://www.dddmag.com/news/2018/01/beta-blockers-may-boost-immunotherapy-help-melanoma-patients-live-longer?et_cid=6229293&et_rid=449166332&type=headline&et_cid=6229293&et_rid=449166332&linkid=content" target="_blank">https://www.dddmag.com/news/2018/01/beta-blockers-may-boost-immunotherapy-help-melanoma-patients-live-longer?et_cid=6229293&et_rid=449166332&type=headline&et_cid=6229293&et_rid=449166332&linkid=content</a></p></blockquote><p></p>
[QUOTE="CoastWatcher, post: 92725, member: 2624"] Researchers at Penn State found that melanoma patients who received immunotherapy while taking a specific type of beta blocker lived longer than patients who received immunotherapy alone. In a follow-up experiment with mice, the researchers saw the same results. Dr. Todd Schell, professor of microbiology and immunology at Penn State College of Medicine, said that because beta blockers are already widely available, the findings -- published in the journal [I]OncoImmunology[/I] -- could indicate a simple way for physicians to better treat their patients. [LIST] [*]"The type of beta blocker we found to be effective against melanoma -- pan beta blockers -- was actually the least prescribed," Schell said. "Most patients are either prescribed beta 1 selective blockers or are not taking beta blockers at all. This means there's a large population of patients who may be eligible to take pan beta blockers while being treated with immunotherapy. And because beta blockers are already FDA approved, it's something we know is safe and can be very quickly implemented in patient care." [*]While there was little difference in how long patients taking beta 1-selective blockers or no beta blockers lived, the results indicate that patients taking pan beta blockers lived significantly longer than the others. Five years after immunotherapy, about 70 percent of patients receiving pan beta blockers were still alive, versus about 25 percent of those taking beta 1-selective blockers or no beta blockers at all. [/LIST] "Beta Blockers May Boost Immunotherapy, Help Melanoma Patients Live Longer," [URL]https://www.dddmag.com/news/2018/01/beta-blockers-may-boost-immunotherapy-help-melanoma-patients-live-longer?et_cid=6229293&et_rid=449166332&type=headline&et_cid=6229293&et_rid=449166332&linkid=content[/URL] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
General Health & Fitness
Health & Wellness
Beta Blockers Extend Life in Melanoma Patients: Penn State Study
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top